Recent Material Events - Salix Pharmaceuticals Ltd (SLXP)

Filing Date	Description
2008-10-07	On October 6, 2008, the company also issued a press release announcing that it presented at the annual meeting of the American College of Gastroenterology results from a phase II chemical trial that demonstrate the clinical utility of rifaximin in tr ...
2008-09-09	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-08-28	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-08-22	On August 18, 2008, Salix Pharmaceuticals, Ltd. entered into a Purchase Agreement with Banc of America Securities LLC, as representative of the several initial purchasers named therein (the “Initial Purchasers”), with respect to Salix’ ...
2008-08-19	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-08-18	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-08-04	The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, ...
2008-07-21	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-07-01	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. ...
2008-06-18	Chief Executive Officer Base salary as of the date of termination for a period of 30 months An amount equal to two times the annual bonus target as of the date of termination Senior Vice President Base salary as of the date of ...